The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
All-Cause Mortality in Randomized Trials of Cancer Screening
Abstract
BACKGROUND: The most widely accepted end point in randomized cancer screening trials is disease-specific mortality. The validity of this end point, however, rests on the assumption that cause of death can be determined accurately. An alternative end point is all-cause mortality, which depends only on the accurate ascertainment of deaths and when they occur. We compared disease-specific and all-cause mortality in published randomized cancer-screening trials to indirectly assess the validity of the disease-specific mortality end point. METHODS: We examined all 12 published randomized trials of cancer screening for which both end points were available (seven of mammography, three of fecal occult blood detection, and two of chest x-ray screening for lung cancer). For each randomized trial, we subtracted disease-specific mortality observed in the screened group from that observed in the control group and all-cause mortality in the screened group from that in the control group. We then compared the differences in these two mortality measures. RESULTS: In five of the 12 trials, differences in the two mortality rates went in opposite directions, suggesting opposite effects of screening. In four of these five trials, disease-specific mortality was lower in the screened group than in the control group, whereas all-cause mortality was the same or higher. In two of the remaining seven trials, the mortality rate differences were in the same direction but their magnitudes were inconsistent; i.e., the difference in all-cause mortality exceeded the disease-specific mortality in the control group. Thus, results of seven of the 12 trials were inconsistent in their direction or magnitude. CONCLUSION: Major inconsistencies were identified in disease-specific and all-cause mortality end points in randomized cancer screening trials. Because all-cause mortality is not affected by bias in classifying the cause of death, it should be examined when interpreting the results of randomized cancer-screening trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281901 · Cited by 3,229
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., James, P. D., & Mangham, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03386-7 · Cited by 2,793
Randomised study of screening for colorectal cancer with faecal-occult-blood test
Kronborg, O., Fenger, C., Olsen, J., Jørgensen, O. D., & Søndergaard, O. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03430-7 · Cited by 2,501
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
(2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,007
Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
Andersson, I., Aspegren, K., Janzon, L., Landberg, T., Lindholm, K., Linell, F., Ljungberg, O., Ranstam, J., & Sigfússon, B. (1988) · BMJ · doi:10.1136/bmj.297.6654.943 · Cited by 916
Cited by
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force
Humphrey, L. L., Helfand, M., Chan, B. K. S., & Woolf, S. H. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_1-200209030-00012 · Cited by 1,137
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Isaacs, C., Kvale, P. A., Reding, D. J., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr500 · Cited by 1,121
Hewitson, P., Glasziou, P., Watson, E., Towler, B., & Irwig, L. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01875.x · Cited by 990
Moynihan, R., G⊘tzsche, P. C., Heath, I., & Henry, D. (2002) · BMJ · doi:10.1136/bmj.324.7342.886 · Cited by 900
Screening for colorectal cancer using the faecal occult blood test, Hemoccult
Hewitson, P., Glasziou, P. P., Irwig, L., Towler, B., & Watson, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001216.pub2 · Cited by 742
Tabar, L., Yen, M.-F., Vitak, B., Chen, H.-H. T., Smith, R. A., & Duffy, S. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13143-1 · Cited by 742
Weight, Weight Gain, and Survival After Breast Cancer Diagnosis
Kroenke, C. H., Chen, W. Y., Rosner, B., & Holmes, M. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.079 · Cited by 670
Effectiveness of the korean national cancer screening program in reducing gastric cancer mortality
Jun, J. K., Choi, K. S., Lee, H.-Y., Suh, M., Park, B., Song, S. H., Jung, K. W., Lee, C. W., Choi, I. J., Park, E.-C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.029 · Cited by 570
Fleming, C., Whitlock, E. P., Beil, T. L., & Lederle, F. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00012 · Cited by 509
Moss, S. M., Cuckle, H., Evans, A., Johns, L., Waller, M., & Bobrow, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69834-6 · Cited by 503
Broeders, M., Moss, S., Nyström, L., Njor, S., Jonsson, H., Paap, E., Massat, N., Duffy, S., Lynge, E., & Paci, E. (2012) · Journal of Medical Screening · doi:10.1258/jms.2012.012078 · Cited by 489
The Reduction in Colorectal Cancer Mortality After Colonoscopy Varies by Site of the Cancer
Singh, H., Nugent, Z., Demers, A. A., Kliewer, E. V., Mahmud, S. M., & Bernstein, C. N. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.052 · Cited by 482
Duffy, S. W., Tabár, L., Chen, H., Holmqvist, M., Yen, M., Abdsalah, S., Epstein, B., Frodis, E., Ljungberg, E., Hedborg‐Melander, C., et al. (2002) · Cancer · doi:10.1002/cncr.10765 · Cited by 429
The randomized trials of breast cancer screening: what have we learned?
Smith, R. A., Duffy, S. W., Gabe, R., Tabar, L., Yen, A. M. F., & Chen, T. H. H. (2004) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.06.014 · Cited by 380
Kratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z.-H., Gao, W., Pham, P. T., Mulvihill, M. S., Ziaei, F., Zhang, H., Su, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61941-7 · Cited by 333
Differential Prognostic Impact of Comorbidity
Read, W. L., Tierney, R. M., Page, N. C., Costas, I., Govindan, R., Spitznagel, E. L. J., & Piccirillo, J. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.040 · Cited by 323
Playdon, M. C., Bracken, M. B., Sanft, T. B., Ligibel, J. A., Harrigan, M., & Irwin, M. L. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv275 · Cited by 309
Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer
Coldman, A., Phillips, N., Wilson, C., Decker, K., Chiarelli, A. M., Brisson, J., Zhang, B., Payne, J., Doyle, G., & Ahmad, R. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju261 · Cited by 295
Bach, P. B., Kelley, M. J., Tate, R. C., & McCrory, D. C. (2003) · Chest · doi:10.1378/chest.123.1_suppl.72s · Cited by 281
Rice, T. W., Ishwaran, H., Hofstetter, W. L., Kelsen, D. P., Apperson-Hansen, C., Blackstone, E. H., & for the Worldwide Esophageal Cancer Collaboration Investigators (2016) · Diseases of the Esophagus · doi:10.1111/dote.12533 · Cited by 280
Obstructive sleep apnea and the prevalence and incidence of cancer
Kendzerska, T., Leung, R. S., Hawker, G., Tomlinson, G., & Gershon, A. S. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.140238 · Cited by 128
Pascucci, D., Sassano, M., Nurchis, M. C., Cicconi, M., Acampora, A., Park, D., Morano, C., & Damiani, G. (2021) · Health Policy · doi:10.1016/j.healthpol.2020.12.006 · Cited by 102
Metadata
- Authors
- Black, W. C.
- Venue
- CancerSpectrum Knowledge Environment
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-02-06
- Volume
- 94
- Issue
- 3
- Pages
- 167-173
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2120488811
- Cited by
- 390
- References
- 34
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.